AI-guided compound design
Generative chemistry trained on hedonic neuroscience, proposing novel molecules across 50+ independent pharmacological targets.
A mechanistic science of human flourishing.
Designing the next generation of therapeutics for wellbeing
Nearly every drug that shifts mood or pleasure was discovered before 1990. The combinatorial space for wellbeing drugs is all but uncharted, and the first sustainable improvement in baseline wellbeing will be the most valuable class of drug ever made.
The Platform
A deliberate search across the least explored space in medicine.
Three capabilities composed into one pipeline — from AI-designed molecule to brain-region-targeted delivery, with objective readouts at every step.
Automated hedonic screening
Continuous, objective, multi-dimensional readouts of mood, pleasure, and pain in animal models.
Region-targeted delivery
Focused ultrasound opens the blood-brain barrier with millimeter precision, placing compounds only where they should act.
Why Now
The economics have changed.
-
AI is radically accelerating biology research.
Target selection, molecular design, and the design and operation of experiments and trials — every step of the discovery loop is now meaningfully faster.
-
A robust patent strategy costs 70–80% less.
Generative drafting and prior-art search bring composition-of-matter coverage within venture-stage budgets.
Traditional pipeline
1.0×
AI-native pipeline
~0.25×
The same coverage, at a quarter of the spend and a fraction of the time.